Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

by September 28, 2023
September 28, 2023
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

Laverock Therapeutics, established to commercialise the gene editing induced gene silencing platform for all human therapeutic applications has announced it has expanded its seed funding round to £13.5M.

This investment was led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.

The funding will enable further development of the GEiGS technology and progression of Laverock’s programmes in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumour responsive T-cell and macrophage based immune therapies, through to in vitro and in vivo validation. A key part of this next phase will be bringing on new members of the team and expanding lab facilities.

David Venables, CEO of Laverock, commented: “GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments.”

Elizabeth Klein, Investment Director at Calculus, said: “We are delighted to support Laverock and its exceptional management team, led by CEO David Venables, as the company embarks on its next phase of expansion, pioneering a new era of programmable advanced therapies. We backed David’s previous venture, Synpromics, which delivered an exceptional return for Calculus investors in 2019. Laverock’s ambitious plans hold tremendous potential for the healthcare sector, and we are excited to be part of the journey.”

Read more:
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

0
FacebookTwitterGoogle +Pinterest
previous post
Ditching the crystal ball on a potential government shutdown
next post
One in five SME owners planning to sell part or all of business by 2025

You may also like

UK faces ‘heightened recession risks’ as interest rates...

August 24, 2023

Tech leaders debate AI skills shortage in Parliament 

February 20, 2024

Church of England divests of fossil fuels as...

June 23, 2023

Rishi Sunak travels to Belfast as NI protocol...

February 17, 2023

Rightmove rejects Rupert Murdoch’s £5.6bn takeover bid as...

September 11, 2024

Scotland to gain two new freeports in Firth...

January 16, 2023

FXGiants Adds Futures to Its Lineup, Now Offering...

November 18, 2024

A third of workers seek jobs that offer...

July 19, 2023

Frasers CEO calls for urgent reform of ‘outdated’...

September 18, 2023

British journalist accuses Barclaycard of anti-semitism over credit...

September 8, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Rescissions: A Small but Welcome Step Toward Spending Discipline

      June 5, 2025
    • DAVID MARCUS: Why Navy ships should not be named for gay rights icons

      June 5, 2025
    • GREGG JARRETT: Biden, the ‘marionette president; and the case of the runaway autopen

      June 5, 2025
    • Trump Practically Bans Travel and Immigration from 12 Countries with Flimsy Security Justifications

      June 5, 2025
    • ‘He’s not a big factor’: Trump’s Senate allies dismiss Elon Musk’s calls to ‘kill the bill’

      June 5, 2025
    • Fears grow that Tata Steel could be excluded from Starmer-Trump trade deal

      June 5, 2025

    Categories

    • Business (8,147)
    • Investing (2,008)
    • Politics (15,523)
    • Stocks (3,127)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved